Filing Details
- Accession Number:
- 0001209191-22-016227
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-04 16:19:19
- Reporting Period:
- 2022-03-02
- Accepted Time:
- 2022-03-04 16:19:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492426 | Horizon Therapeutics Public Ltd Co | HZNP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1512985 | A. Michael Desjardin | C/O Horizon Therapeutics Plc, 70 Saint Stephen?S Green Dublin L2 D02 E2X4 | Evp, Technical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2022-03-02 | 21,482 | $97.05 | 116,078 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2022-03-02 | 13,518 | $97.42 | 102,560 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.24 to $97.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.26 to $97.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
